Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
AORT: An affiliate filed a Form 144 notice to sell up to 17,580 shares of common stock, reflecting an aggregate market value of $784,400.26. The filing lists an approximate sale date of 11/10/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer as compensation. The filer also reported sales in the past three months: 12,500 shares on 08/15/2025 for gross proceeds of $528,991.00. Shares outstanding were 47,374,939; this is a baseline figure, not the amount being sold.
Artivion (AORT) received a Form 144 notice from a shareholder for a proposed sale of 10,000 common shares with an aggregate market value of $461,800. The filing lists an approximate sale date of 11/11/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities to be sold were acquired from the issuer via an option granted on 11/08/2022, with acquisition and cash payment dated 11/11/2025. Shares outstanding were 47,374,939.
The filer reported prior sales in the last three months: 23,356 shares on 08/12/2025 for $1,004,605.97 and 10,000 shares on 08/25/2025 for $443,700.00.
Form 144 notice of proposed sale: A shareholder filed to sell up to 2,960 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $132,071.94. The filing lists an approximate sale date of 11/11/2025 on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer, in an amount of 2,960 shares, treated as compensation. Shares outstanding were 47,374,939 at the time referenced in the form; this is a baseline figure, not the amount being sold.
The person for whose account the securities are to be sold reported prior sales in the past three months: 23,356 shares on 08/12/2025 for gross proceeds of $1,004,605.97, and 10,000 shares on 08/25/2025 for gross proceeds of $443,700.00.
Artivion (AORT) received a Form 144 notice indicating a planned sale of up to 1,789 shares of common stock. The filing lists an aggregate market value of $79,823.21 and an approximate sale date of 11/10/2025 on the NYSE through Fidelity Brokerage Services LLC.
The seller acquired these shares on 11/07/2025 via restricted stock vesting from the issuer as compensation. Shares outstanding were 47,374,939, providing scale relative to the proposed sale.
Artivion (AORT): Notice of proposed sale under Rule 144. A filing indicates an intent to sell 3,373 common shares, with an approximate sale date of 11/10/2025. The filing lists an aggregate market value of $150,499.55, with trading on the NYSE.
The shares were acquired on 11/07/2025 via restricted stock vesting from the issuer, recorded as compensation. As context, 47,374,939 shares were outstanding. In the past three months, the named seller reported a sale of 10,802 shares on 08/12/2025 for $471,752.51.
This is an administrative notice of a potential sale under Rule 144 and does not itself execute a transaction.
Morgan Stanley filed Schedule 13G/A (Amendment No. 2) reporting beneficial ownership of 2,074,975 shares of Artivion, Inc. (AORT) common stock, representing 4.4% of the class as of the reporting event dated 09/30/2025. The filing states Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class.
The filing lists shared voting power: 208,344 shares and shared dispositive power: 2,074,975 shares, with 0 shares under sole voting or dispositive power. The certification indicates the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Artivion (AORT) reported third‑quarter 2025 results with total revenues of $113.4 million, up 18% year over year. Medical devices drove growth, led by aortic stent grafts $39.6 million (+38%) and On‑X $26.8 million (+25%), while preservation services contributed $25.7 million (+5%). Gross margin was $74.4 million, and operating income rose to $12.5 million.
Net income was $6.5 million (diluted EPS $0.13) versus a loss a year ago, aided by a $3.5 million PerClot sales milestone gain. Operating cash flow reached $20.3 million year to date, ending cash was $73.4 million. The company eliminated its $100.0 million Convertible Senior Notes via exchanges into ~4.35 million shares and small residual settlement, reducing interest expense. A credit amendment extended maturities to January 18, 2031 and lowered interest margins; total principal debt stood at $220.0 million with long‑term debt (net) of $214.9 million. Shares outstanding were 47,374,939 as of October 31, 2025.
Artivion, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release is provided under Item 2.02 and is attached as Exhibit 99.1.
The company stated that the information is furnished, not filed, and is not incorporated by reference unless expressly noted. It also included forward‑looking statements subject to the Private Securities Litigation Reform Act safe harbor and directed readers to risk factors in its most recent Form 10‑K and subsequent filings.
Artivion, Inc. furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release is provided under Item 2.02 and is attached as Exhibit 99.1.
The company stated that the information is furnished, not filed, and is not incorporated by reference unless expressly noted. It also included forward‑looking statements subject to the Private Securities Litigation Reform Act safe harbor and directed readers to risk factors in its most recent Form 10‑K and subsequent filings.
BlackRock, Inc. filed Amendment No. 5 to Schedule 13G reporting beneficial ownership of 5,977,264 shares of Artivion, Inc. (AORT) common stock, representing 12.7% of the class as of 09/30/2025.
BlackRock reports sole voting power over 5,912,256 shares and sole dispositive power over 5,977,264 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. The interest of iShares Core S&P Small-Cap ETF in Artivion’s common stock is noted as more than five percent of outstanding shares.
Artivion, Inc. entered into two real estate purchase and sale agreements on September 26, 2025 to buy facilities in Austin, Texas that support and expand its manufacturing operations. The company agreed to purchase from 1300 East Anderson Lane, Ltd. two office buildings it currently leases, which house its On-X manufacturing operation, for a cash price of $12.05 million, including the underlying land and certain equipment, totaling about 75,000 square feet of mixed-use space.
Artivion also agreed to purchase an adjacent building from Sentinel Austin I, LLC for a cash price of $8.45 million, adding roughly 87,000 square feet to its footprint to accommodate rising capacity needs in the coming years. Each agreement includes a feasibility period—45 days for the 1300 Property and 100 days for the 1200 Property—during which Artivion can decide at its sole discretion not to proceed, with closings expected on or before 30 days after each feasibility period, subject to customary conditions.